Abstract
The promyelocytic leukaemia (PML) tumour-suppressor protein potentiates p53 function by regulating post-translational modifications, such as CBP-dependent acetylation1,2 and Chk2-dependent phosphorylation, in the PML-Nuclear Body (NB)3. PML was recently shown to interact with the p53 ubiquitin-ligase Mdm2 (refs 4â6); however, the mechanism by which PML regulates Mdm2 remains unclear. Here, we show that PML enhances p53 stability by sequestering Mdm2 to the nucleolus. We found that after DNA damage, PML and Mdm2 accumulate in the nucleolus in an Arf-independent manner. In addition, we found that the nucleolar localization of PML is dependent on ATR activation and phosphorylation of PML by ATR. Notably, in Pmlâ/â cells, sequestration of Mdm2 to the nucleolus was impaired, as well as p53 stabilization and the induction of apoptosis. Furthermore, we demonstrate that PML physically associates with the nucleolar protein L11, and that L11 knockdown impairs the ability of PML to localize to nucleoli after DNA damage. These findings demonstrate an unexpected role of PML in the nucleolar network for tumour suppression.
Similar content being viewed by others
Main
The mechanisms promoting the up-regulation and transcriptional activation of p53 are critical for modulating its role in tumour suppression. The product of the mdm2 proto-oncogene physically interacts with p53 and is a negative regulator of p53 in cells that are not subjected to stress. It does this by functioning as a p53 ubiquitin ligase7. Disruption of the p53âMdm2 complex is achieved in several ways, such as phosphorylation of p53 or Mdm2 (or both) and sequestration of either p53 or Mdm2 to separate sub-nuclear compartments7. These mechanisms can be differentially utilized after distinct cellular stresses; for example, nucleolar sequestration of Mdm2 can occur after replicative senescence8 or after inhibition of RNA polymerase I by actinomycin D (nucleolar stress)9.
The PML gene encodes a tumour suppressor involved in the pathogenesis of acute promyelocytic leukemia (APL)10. The PML protein localizes to multi-protein sub-nuclear structures termed PML-NBs11. Numerous proteins associate dynamically with PML in PML-NBs after specific stimuli. In particular, after oncogenic stress and DNA damage induced by Îł-irradiation, PML functions as a p53 transcriptional co-activator by recruiting it to the PML-NBs1,2,12. Here, it facilitates acetylation of p53 (on Lys-382), mediated by the acetyl-transferase CBP1,2. However, we found that PML-IV (the PML isoform that binds p53; refs 2, 13) could function as a p53 transcriptional co-activator, even after substitution of critical p53 lysine residues with arginines (p53K382R, p53K320R and p53K5R mutants; see Supplementary Information, Fig. S1). These results suggest that PML may potentiate p53 activity through additional mechanisms.
We reasoned that PML might directly influence p53 protein stability. Indeed, increasing amounts of PML induced the accumulation of p53 and p53 target genes, such as p21 (Fig. 1a), by increasing the half-life of p53 (Fig. 1b). Importantly, overexpression of PML in p53/Mdm2 double-null (Mdm2â/â/p53â/â) mouse embryonic fibroblasts (MEFs) did not result in the accumulation of transfected p53 (Fig. 1c), but prevented the reduction in p53 levels caused by cotransfection of human Mdm2 (Hdm2; Fig. 1d). These results demonstrate that PML can stabilize p53 by antagonizing Mdm2 function.
The stabilization of p53 in wild-type and Pmlâ/â primary cells was examined after the introduction of p53-dependent apoptotic stimuli. In Pmlâ/â MEFs, the accumulation of p53 after treatment with the topoisomerase inhibitor doxorubicin and the cross-linking agent mitomycin C was impaired (Fig. 1e). The phosphorylation of p53 on Ser 18 (Ser 15 in human p53) and acetylation on Lys 320 and Lys 382 paralleled the levels of total p53 in MEFs treated with doxorubicin and mitomycin C (see Supplementary Information, Fig. S2). This suggested that these p53 post-translational modifications were not defective; thus, they could not account for the defect in p53 accumulation that was observed in Pmlâ/â MEFs. As PML promoted p53 stabilization by counteracting the function of Mdm2, we reasoned that the absence of Pml might result in an increase in p53 ubiquitination after DNA damage. Wild-type and Pmlâ/â cells were transfected with haemagglutinin fused to ubiquitin (HAâUb) and treated with doxorubicin, as well as the proteasome inhibitor MG132 (to prevent p53 degradation). Immunoprecipitation of endogenous p53 identified a marked increase in p53âHAâUb complexes in Pmlâ/â, cells compared with wild-type cells (Fig. 1f). Therefore, after DNA damage in Pmlâ/â cells, p53 stability is impaired and p53 ubiquitination increases. Interestingly, wild-type MEFs treated with doxorubicin and mitomycin C showed a significant up-regulation of Pml, which coincided with the accumulation of p53 (see Supplementary Information, Fig. S2). Notably, doxorubicin- and mitomycin-C-induced apoptosis was markedly impaired in the absence of Pml (Fig. 1g). Therefore, PML is important for the accumulation of p53 and the induction of apoptosis after DNA damage.
To understand the mechanisms underlying p53 stabilization by PML, we analysed the localization of PML, Mdm2 and p53 after DNA damage. Surprisingly, in WI38 (normal human embryonic fibroblasts) cells and wild-type MEFs treated with doxorubicin, PML concentrated in the nucleoli, as demonstrated by co-localization with nucleolar markers (Fig. 2a, b). In the majority of cells, PML accumulated at the periphery of the nucleolus. Accumulation of PML in the nucleolus was not accompanied by a disappearance of the PML-NBs, and this accumulation was also observed after mitomycin C treatment (data not shown). Six hours after doxorubicin treatment, nucleoli could not be detected by immunofluorescence microscopy with nucleolar markers (data not shown), as noted after other cellular stresses14. However, nucleoli reformed at later times (onwards of 12 h), when PML was found to colocalize with nucleolar proteins (Fig. 2a, b). SUMO-1 localized to the nucleolus with PML after doxorubicin treatment (data not shown), suggesting that nucleolar PML may be SUMO-modified.
ATM and ATR kinases are the major regulators of a cascade of cellular responses to DNA damage that result in either cell-cycle arrest and DNA repair or apoptosis15. Therefore, we tested whether PML accumulation in the nucleolus was part of an ATM- or ATR-dependent checkpoint response. A dose of caffeine that is known to inhibit both ATM and ATR16 markedly blocked the localization of PML to the nucleolus after doxorubicin treatment (Fig. 2c, left panel). To determine whether PML localization was dependent on the function of ATM, ATR, or both, Atmâ/â primary cells were used17. PML localization in the nucleolus was unaffected by Atm inactivation (data not shown). A human cell line stably transfected with a tetracycline-inducible dominant-negative form of ATR (ATR-DN; see Methods) was then used18. Induction of ATR-DN by doxycycline significantly reduced the accumulation of PML in the nucleolus after doxorubicin treatment (Fig. 2c, right). Endogenous PML immunoprecipitated from doxorubicin-treated wild-type MEFs, was recognized with an antibody against proteins phosphorylated by ATM or ATR (data not shown). In addition, PML was overexpressed in ATR-DN fibroblasts treated with doxorubicin in the presence or absence of doxycycline. Immunoprecipitated PML was recognized by the anti-phospho-ATM/ATR antibody, but only after treatment with doxorubicin and in the absence of doxycycline (Fig. 2d). Finally, ATR kinase assays were performed with purified His-tagged PML (HisâPML) and cell extracts from U2OS cells expressing inducible wild-type or dominant-negative ATR19. PML was phosphorylated after induction of wild-type, but not dominant-negative, ATR (Fig. 2e). Furthermore, this phosphorylation was inhibited by caffeine (Fig. 2f), demonstrating that PML is a direct target of ATR. In conclusion, PML is phosphorylated and accumulates in the nucleolus after DNA damage as part of a checkpoint response that depends on ATR activation.
The localization of Mdm2 and p53 after DNA damage was examined. Mdm2 accumulated in the nucleolus after doxorubicin treatment and colocalized with nucleolar PML, as shown by triple-staining of Hdm2, PML and nucleophosmin (NPM; Fig. 3a). Importantly, nucleolar localization of both PML and Mdm2 after doxorubicin treatment also occurred in Arfâ/â MEFs (Fig. 3b, c). Furthermore, endogenous PML and Mdm2 were coimmunoprecipitated from WI38 cells after DNA damage at times when they were found to colocalize in the nucleolus (Fig. 3d; also see Fig. 2a). In contrast, p53 did not accumulate in the nucleolus after doxorubicin treatment (data not shown). Together, these data demonstrate that after DNA damage, Mdm2 is sequestered in the nucleolus in an ARF-independent manner, where it interacts with PML.
Therefore, we tested whether sequestration of Mdm2 to the nucleolus after DNA damage was PML-dependent. The percentage of Pmlâ/â MEFs displaying nucleolar Mdm2 after doxorubicin treatment was markedly reduced when compared with wild-type MEFs (Fig. 3e). To further quantify these differences, nucleoli were isolated from wild-type and Pmlâ/â MEFs before and after doxorubicin treatment. Mdm2 was found in the nucleoplasm of both wild-type and Pmlâ/â cells (Fig. 3f). However, after doxorubicin treatment, a percentage of Mdm2 could be detected in the nucleolar fraction of wild-type cells, but not Pmlâ/â cells (Fig. 3f). These findings demonstrate that PML is critical for nucleolar accumulation of Mdm2 after DNA damage.
Our data imply that PML may promote p53 stabilization by sequestering Mdm2. To test this hypothesis, we assessed whether PML and Mdm2 interact directly and, if so, whether a mutant of PML that binds Mdm2, but not p53, stabilizes p53. PML and Mdm2 interacted in p53-null H1299 cells, even in the absence of p53 (Fig. 4a). Glutathione S-transferase (GST) pull-down assays with GST or GSTâMdm2, as well as deletion mutants of PML, demonstrated that the two proteins interact directly. The binding site for Mdm2 resided around the coiled-coil motif of PML, which is shared by all PML isoforms (Fig. 4b). p53, however, binds to the extreme carboxyl terminus of PML-IV13 (Fig. 4b). Next, a PML mutant (PML mutant 5 in Fig. 4b; MT-PML) that binds Mdm2, but not p53, was examined. This mutant lacks the nuclear localization signal (NLS) and forms cytoplasmic aggregates when overexpressed (Fig. 4c). MT-PML was used in these experiments (rather than other PML isoforms), because all PML isoforms have been reported to recruit p53 to the PML-NB20. MT-PML recruited endogenous Mdm2 to the cytoplasm (Fig. 4c, top), but failed to recruit cotransfected p53 (Fig. 4c, bottom). Similar results were obtained with Pmlâ/â MEFs (data not shown). Notably, MT-PML stabilized p53 to the same extent as full-length PML (FL-PML; Fig. 4d, left). Interestingly, both FL-PML and MT-PML promoted the accumulation of Hdm2 (Fig. 4d, right), suggesting that PML can inhibit Hdm2 self-ubiquitination/degradation, as previously shown for ARF21 and the ribosomal protein L11 (ref. 9). Together, these results suggest that PML can promote accumulation of p53 by sequestering Mdm2 in the absence of direct PML/p53 binding.
During replicative senescence, the tumour-suppressor protein ARF binds to Mdm2 and sequesters it in the nucleolus8. Nucleolar localization of Mdm2 after actinomycin D treatment, however, is ARF-independent and is mediated by the nucleolar protein L11 (ref. 9). Actinomycin D treatment also induced the localization of PML to the nucleolus (data not shown). Therefore, we hypothesized that both Mdm2 and PML might interact with L11 after DNA damage, and that L11 might mediate nucleolar localization of PML. Endogenous L11 co-immunoprecipitated with overexpressed PML in NIH 3T3 fibroblasts (Fig. 5a) and H1299 cells (data not shown). PML deletion mutants that lacked the C-terminal region could no longer interact with L11 (Fig. 5b), suggesting that L11 binding does not overlap with the Mdm2-binding region (Fig. 4b). In vitro binding assays demonstrated that PML and L11 can interact directly (Fig. 5c). Thus, we reasoned that endogenous PML and L11 might interact in the nucleolus after doxorubicin treatment. Low levels of PML were co-immunoprecipitated with an anti-L11 antibody in wild-type MEFs after doxorubicin treatment (Fig. 5d, top). Importantly, the amount of PML from isolated nucleoli that co-immunoprecipitated with L11 was considerably higher than that from whole-cell extracts (Fig. 5d, compare bottom and top panels, and see graph). Thus PML and L11 interact specifically in the nucleoli.
Next, we assessed whether L11 is required for the nucleolar accumulation of PML. Small-interfering RNAs (siRNAs) knocked-down L11 expression in WI38 cells. Two siRNAs were tested, and both produced similar reductions in L11 expression (up to 50%), while leaving other nucleolar proteins unaffected (Fig. 5e). PML nucleolar localization was analysed in cells treated with control siRNAs or L11 siRNAs after doxorubicin treatment. The number of cells displaying colocalization of PML with nucleolin (or NPM; data not shown) was reduced markedly in L11 siRNA-treated cells (Fig. 5f). As L11 interacts with Mdm2 after treatment with actinomycin D9,22, we reasoned that Mdm2 and L11 might also interact after doxorubicin treatment; furthermore, PML might be required for this interaction. Overexpressed Mdm2 and L11 co-immunoprecipitated from both wild-type and Pmlâ/â cells; however, doxorubicin treatment only increased this interaction in the presence of PML (see Supplementary Information, Fig. S3). Together, these results demonstrate that PML interacts with L11 in the nucleolus and that this interaction is important for the localization of PML to the nucleolus.
Our analysis leads to three major conclusions. First, PML (until now considered to be a NB protein) can be found in a distinct subcellular compartment (the nucleolus) after cellular stress. It is important to note that PML accumulates in the nucleolus after treatment with specific DNA-damaging agents (for example, doxorubicin, but not Îł-irradiation23; see Supplementary Information, Fig. S4). The nucleolar localization of PML is triggered by activation of the checkpoint kinase ATR, consistent with ATR activation being a major event in the induction of S/G2 checkpoints after exposure to topoisomerase inhibitors24. This observation, along with the finding that PML is a direct target of Chk2 phosphorylation after Îł-irradiation25, suggests that the localization and function of PML are regulated by different checkpoints in response to distinct apoptotic stimuli. Second, the accumulation of PML in the nucleolus is ARF-independent and, at least in part, dependent on the nucleolar protein L11. As nucleolar accumulation of PML is reduced but not abrogated after L11 knockdown, this suggests that other proteins may also function to dock PML at the nucleolus. Finally, PML is required for Mdm2 nucleolar localization and, in turn, p53 stabilization after DNA damage. As L11 can interact directly with Mdm2 and PML, it is possible that both proteins participate in a larger nucleolar complex to induce Mdm2 sequestration. Our data add complexity to the original working model by which PML regulates p53 function in the NB, and the PML-NB represents a site for modification and activation of p53 (refs 26, 27).
Methods
Cell culture.
MEFs were prepared from embryos at day 13.5 of development (E13.5). Early passage (3â5) MEFs were used in all experiments, except as indicated. Wild-type and Pmlâ/â MEFs were immortalized using a 3T9 protocol and maintained in culture up to passage 30. p53 function was considered normal, as the protein was induced by doxorubicin treatment and cells displayed sensitivity to doxorubicin. H1299, NIH 3T3, 293T and WI38 cells were obtained from the American Type Culture Collection. The GM847 ATR-DN (dominant negative) cell line â an SV40-immortalized human fibroblast line expressing the ATR dominant-negative kinase under the control of a tetracycline-inducible system â was kindly provided by W. Cliby17. U2OS wild-type ATR and ATR-DN were kindly provided by S. Schreiber18. Induction of wild-type ATR and ATR-DN was achieved by 48-h-treatment with 1 ÎźM doxycycline (Sigma, Saint Louis, MO). The Atm-null cell line 743 was a kind gift from M. Turker16. G. Lozano and M. van Lohuizen kindly provided mdm2â/â/p53â/â and Arfâ/â MEFs, respectively. Primary and established cells were cultured in DMEM supplemented with 10% foetal bovine serum, 4.5 mg mlâ1 glucose and L-glutamine. Cells were treated with 0.5â2 ÎźM doxorubicin depending on the sensitivity of the cell type (0.5â1 ÎźM for MEFs or immortalized MEFs; 2 ÎźM for WI38 cells; 1 ÎźM for NIH3T3 cells; 1 ÎźM for Atm-null cells; and 1 ÎźM for ATR-DN cells) and 50 mg mlâ1 mitomycin C, (Sigma). Cycloheximide and caffeine (Sigma) were used at 25 ÎźM and 4 mM, respectively, for the indicated times. MG132 (Calbiochem, La Jolla, CA) was used at 10 ÎźM.
Plasmids, cell transfection and transactivation assays.
pCMV-Tag2BâPML-IV expresses PML isoform IV under the control of the CMV promoter. pCMVâWT-p53 and pCMVâp53K5R (a p53 mutant in which lysines 370, 372, 373, 381 and 382 are substituted by arginines) expression vectors were a generous gift from W. Gu. PCMVâp53K320R and pCMVâp53K382R were created by site-directed mutagenesis to introduce a LysâArg substitution at position 320 or 382, respectively. PML-deletion mutants were as described2, except for mutant 5, which was created by site-directed mutagenesis. CMVâHdm2 was a gift from G. Lozano. pBaxâluc, p21âluc and pMDM2âluc reporter plasmids were a kind gift from C. Di Como and C. Prives. GSTâMdm2 was from A. Weismann. HisâPML was created by cloning PML-IV into pET-33b (Novagen, Madison, WI). Transient transfections were performed with the Effectene transfection reagent (Qiagen, Valencia, CA) according to the manufacturer's protocol. For transfections in H1299 cells, 50 ng of p53 were cotransfected with 50, 100 and 500 ng of PML-IV, with or without 500 ng of Hdm2. pEGFP (100 ng) or renilla- (50 ng) expressing plasmids were cotransfected to normalize for transfection efficiency. For transactivation assays, 200 ng of reporter plasmid was used and luciferase activity was assayed 24 h post-transfection. For Mdm2âL11 interaction, wild-type and Pmlâ/â immortalized MEFs were transfected with 2 Îźg CMVâMdm2 and 4 Îźg CMVâL11. 24 h post-transfection, cells were treated with 1 ÎźM doxorubicin for 18 h.
Western blotting, immunoprecipitation, in vitro protein interactions and ATR kinase assay.
For western blot analysis, cells were lysed in ice-cold RIPA buffer containing a complete protease inhibitor cocktail (Boehringer Mannheim, Mannheim, Germany). Lysates were centrifuged to clear cell debris and 20â40 Îźg of lysate was used for analysis. The following antibodies were used: anti-human-p53 (DO-1; Santa Cruz, Santa Cruz, CA), anti-mouse-p53 (CM5; Novocastra, Newcastle, UK), anti-phospo-p53 (Ser 15; New England Biolabs, Beverly, MA), anti-Flag-M2 (Sigma), anti-Mdm2 (SMP14; Santa Cruz), anti-human-PML (PG-M3; Santa Cruz), rabbit anti-PML (kindly provided by K. S. Chang), anti-mouse PML (S36 and S37 monoclonal antibodies; kindly provided by S. Lowe), anti-GFP (Clontech, Palo Alto, CA), anti phospho-Ser/Thr-ATM/ATR (Cell Signaling, Beverly, MA) and anti-HA (Covance, Berkeley, CA). For co-immunoprecipitation, cells were lysed in immunoprecipitation (IP) buffer (150 mM NaCl, 50 mM Tris-HCl at pH 7.5 and 1% NP-40), supplemented with a complete protease-inhibitor cocktail. The lysate was precleared by incubation with protein-Gâ or protein-AâSepharose beads (Amersham Biosciences, Piscataway, NY) and incubated with anti-Flag antibody, anti-human PML antibody (PG-M3) or anti-L11 antibody9 overnight at 4°C before incubation with protein-Gâ or protein-AâSepharose for 1 h. Immunoprecipitates were washed five times with ice-cold IP buffer and resolved by SDSâPAGE. Western blotting was performed according to standard procedures. For GST pull-down assays, in vitro-translated products were generated using the TNT Coupled System (Promega, Madison, WI). 35S-labelled wild-type PML and PML mutants were incubated with GST and GSTâMdm2 in IP buffer for 2 h at 4°C. Beads were washed five times with IP buffer, and proteins were eluted with SDS sample buffer and resolved by SDSâPAGE before autoradiography. For ATR kinase assays, U2OS cells expressing wild-type ATR or ATR-DN were treated with doxycyclin for 48 h and ATR was immunoprecipitated from 2 mg of cell extract with anti-Flag antibody. Kinase assays were performed as previously described18 with 1 Îźg purified His-PML as a substrate. Proteins were separated by SDSâPAGE, transferred onto membranes and exposed for autoradiography, as well as western blot analysis with an anti-Flag antibody.
Isolation of nucleoli.
Nucleoli were prepared from wild-type and Pmlâ/â immortalized MEFs grown on 10 Ă 14 cm plates, as described28. Isolated nucleoli were resuspended in RIPA buffer and centrifuged at 13,000g to eliminate insoluble material. For L11âPML coimmunoprecipitations, nucleoli were resuspended in IP buffer and immunoprecipitated with anti-L11 antibody.
Immunofluorescence and confocal microscopy.
Cells were grown on coverslips and treated as indicated. Cells were fixed in 4% paraformaldehyde for 10 min before permeabilization in PBS containing 0.1% Triton X-100 for 2 min. The antibodies used for immunofluorescence microscopy were: anti-human PML (PG-M3; Santa Cruz), anti-mouse PML (S36 and S37 monoclonal antibodies), anti-Mdm2 (SMP14; Santa Cruz), anti-nucleolin (4E2; Research Diagnostics, Flanders, NJ), anti-p19Arf (R562; Abcam, Cambridge, MA), anti-p53 (Ab-3; Oncogene Research Products, Darmstadt, Germany). Double staining was performed as indicated. For detection, cells were incubated with FITC-conjugated anti-mouse antibodies and Cy5-conjugated anti-rabbit antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA). For triple staining, the antibodies used were: rabbit anti-PML (kindly provided by K. S. Chang), mouse anti-Mdm2 (SMP14; Santa Cruz) and goat anti-B23 (C-19; Santa Cruz). The secondary antibodies used for triple staining were: Alexa Fluor-405 anti-rabbit, Alexa Fluor-488 anti-mouse and Cy5-conjugated anti-goat (Molecular Probes, Eugene, OR). Slides were analysed by confocal microscopy.
L11 siRNA.
siRNA oligonucleotides for L11 were obtained from Dharmacon (Lafayette, CO) in 2â˛-deprotected, annealed and desalted duplex form. The target sequences were nucleotides 198â218 (siRNA-1) and 262â282 (siRNA-2). WI38 cells were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Cells were treated with doxorubicin 12 h after siRNA-transfection, fixed and analysed 36 h after treatment. Primers for L11 RTâPCR analysis were: 5â˛-GCGCAGGATCAAGGTGAA-3â˛; 5â˛-TTATTTCGGAGGAAGGAT-3â˛.
Note: Supplementary Information is available on the Nature Cell Biology website.
References
Pearson, M. et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406, 207â210 (2000).
Guo, A. et al. The function of PML in p53-dependent apoptosis. Nature Cell Biol. 2, 730â736 (2000).
Louria-Hayon, I. et al. PML protects p53 from Mdm2-mediated inhibition and degradation. J. Biol. Chem. 278, 33134â33141 (2003).
Wei, X. et al. Physical and functional interactions between PML and MDM2. J. Biol. Chem. 278, 29288â29297 (2003).
Zhu, H., Wu, L. & Maki, C.G. MDM2 and PML antagonize each other through their direct interaction with p53. J. Biol. Chem. 278, 49286â49292 (2003).
Kurki, S., Latonen, L. & Laiho, M. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J. Cell Sci. 116, 3917â3925 (2003).
Oren, M. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274, 36031â36034 (1999).
Weber, J.D., Taylor, L.J., Roussel, M.F., Sherr, C.J. & Bar-Sagi, D. Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol. 1, 20â26 (1999).
Lohrum, M.A., Ludwig, R.L., Kubbutat, M.H., Hanlon, M. & Vousden, K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3, 577â587 (2003).
Salomoni, P. & Pandolfi, P.P. The role of PML in tumor suppression. Cell 108, 165â170 (2002).
Jensen, K., Shiels, C. & Freemont, P.S. PML protein isoforms and the RBCC/TRIM motif. Oncogene 20, 7223â7233 (2001).
Ferbeyre, G. et al. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14, 2015â2027 (2000).
Fogal, V. et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19, 6185â6195 (2000).
Rubbi, C.P. & Milner, J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 22, 6068â6077 (2003).
Abraham, R.T. Cell-cycle-checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15, 2177â2196 (2001).
Sarkaria, J.N. et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59, 4375â4382 (1999).
Gage, B.M. et al. Spontaneously immortalized cell lines obtained from adult Atm-null mice retain sensitivity to ionizing radiation and exhibit a mutational pattern suggestive of oxidative stress. Oncogene 20, 4291â4297 (2001).
Cliby, W.A. et al. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell-cycle checkpoints. EMBO J. 17, 159â169 (1998).
Nghiem, P., Park, P.K., Kim, Y., Vaziri, C. & Schreiber, S.L. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc. Natl Acad. Sci. USA 98, 9092â9097 (2001).
Bischof O., Kirsh O., Pearson M., Itahana K., Pelicci P.P. & Dejean A. Deconstructing PML-induced premature senescence. EMBO J. 21, 3358â3369 (2002).
Stott F.J. et al. The alternative product of the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001â5014 (1998).
Zhang, Y. et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 23, 8902â8912 (2003).
Carbone, R., Pearson, M., Minucci, S. & Pelicci, P.G. PML NBs associate with the hMre11 complex and p53 at sites of irradiation-induced DNA damage. Oncogene 21, 1633â1640 (2002).
Cliby, W.A., Lewis, K.A., Lilly, K.K. & Kaufmann, S.H. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J. Biol. Chem. 277, 1599â1606 (2002).
Yang, S., Kuo, C., Bisi, J.E. & Kim, M.K. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nature Cell Biol. 4, 865â870 (2002).
Gostissa, M., Hofmann, T.G., Will, H. & Del Sal, G. Regulation of p53 functions: let's meet at the nuclear bodies. Curr. Opin. Cell Biol. 15, 351â357 (2003).
Bernardi, R. & Pandolfi, P.P. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22, 9048â9057 (2003).
Andersen, J.S. et al. Directed proteomic analysis of the human nucleolus. Curr. Biol. 12, 1â11 (2002).
Acknowledgements
We are indebted to I. Guernah, A. Guo, P. Salomoni, F. Bernassola, and S. Grisendi for suggestions during the course of this work and critical reading of the manuscript. We are grateful to W. Cliby, C. Di Como, W. Gu, A. Levine, S. Lowe, G. Lozano, C. Prives, S. Schreiber, M. Turker, M. van Lohuizen and A. Weismann for reagents and advice. We thank Y. Haupt for useful discussion. R.B. and P.P.S. were supported by T32 training grants from the National Institutes of Health. P.P.S. is also a recipient of an ASCO Young Investigator Award and a CALGB Oncology Fellows Award. This work was supported by the award of a National Institutes of Health grant RO1 CA-71692 to P.P.P.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Figures
Figures S1, S2, S3 and S4 (PDF 726 kb)
Rights and permissions
About this article
Cite this article
Bernardi, R., Scaglioni, P., Bergmann, S. et al. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6, 665â672 (2004). https://doi.org/10.1038/ncb1147
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb1147
This article is cited by
-
Microgravity and space radiation inhibit autophagy in human capillary endothelial cells, through either opposite or synergistic effects on specific molecular pathways
Cellular and Molecular Life Sciences (2022)
-
TRAIL-receptor 2âa novel negative regulator of p53
Cell Death & Disease (2021)
-
Liquid-like droplet formation by tumor suppressor p53 induced by multivalent electrostatic interactions between two disordered domains
Scientific Reports (2020)
-
The RepIDâCRL4 ubiquitin ligase complex regulates metaphase to anaphase transition via BUB3 degradation
Nature Communications (2020)
-
Regulation of PKCβ levels and autophagy by PML is essential for high-glucose-dependent mesenchymal stem cell adipogenesis
International Journal of Obesity (2019)